Big pharma partners flock to Adimab for antibodies
This article was originally published in Scrip
Executive Summary
The already impressive list of companies that have partnered with the antibody technology firm Adimab has just got even longer. Biogen Idec and Novo Nordisk each signed up to milestone and royalty-based deals under which the four-year-old firm will identify fully human antibodies against two targets provided by its respective partners. Adimab also receives upfront payments from its partners.